E2F1在前列腺癌中的调控作用  

The regulatory role of E2F1 in prostate cancer

作　　者：张明祎 季鸣 陈晓光 ZHANG Ming-yi;JI Ming;CHEN Xiao-guang(State Key Laboratory of Bioactive Substances and Functions of Natural Medicines/Beijing Key Laboratory of Non-clinical Drug Metabolism and PK/PD Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院、北京协和医学院药物研究所,天然药物活性物质与功能国家重点实验室/创新药物非临床药物代谢及PK/PD研究北京市重点实验室,北京100050

出　　处：《药学学报》2021年第3期654-660,共7页Acta Pharmaceutica Sinica

基　　金：“十三五”国家“重大新药创制”科技重大专项(2018ZX09711001-003)。

摘　　要：细胞周期相关转录因子1 (E2F transcription factor 1, E2F1)是细胞周期相关转录因子家族的重要一员。参与人体生命活动中重要调控过程,如细胞周期、增殖、凋亡和代谢等。E2F1活性与肿瘤抑制因子视网膜母细胞瘤蛋白(retinoblastoma, RB)依赖的细胞周期G1/S期调控有关。近年来许多研究显示, E2F1在前列腺癌组织细胞中呈高表达,起到促癌基因的作用,其表达水平与前列腺癌的发生、发展及不良临床预后密切相关。雄激素受体(androgen receptor, AR)是前列腺癌生长和进展的主要驱动因素, AR通路的改变在前列腺癌病理进展过程中发挥关键作用。本文结合国内外最新研究报道,对E2F1主要通路在前列腺癌细胞中调控作用的研究进展作一综述。E2 F transcription factor 1(E2 F1) is a major member of the E2 F transcription factor family and participates in a wide range of physiological regulatory processes, such as cell cycle, survival, apoptosis, and metabolism. It is proved that the activity of E2 F1 is related to the G1/S phase regulation of the cell cycle dependent on tumor suppressor retinoblastoma protein(RB). Recent studies have shown that E2 F1 is highly expressed in prostate cancer cells, manifested as an oncogene, and its expression level is closely related to the occurrence,development, and poor clinical prognosis of prostate cancer. Androgen receptor(AR) is the main driving factor for the growth and progression of prostate cancer, and the changes of AR pathway play a key role in the pathological progression of prostate cancer. This article provide a systematic and comprehensive summary on recently published articles to review the role of the E2 F1 pathway in prostate cancer.

关 键 词：前列腺癌 细胞周期相关转录因子1 视网膜母细胞瘤蛋白 雄激素受体 

分 类 号：R966[医药卫生—药理学]